| Individualising therapy for drug-sensitive tuberculosis | Lancet Respiratory Medicine | 3 days | save |  |  |  |  |
| Breathless and dying on Mount Everest | Lancet Respiratory Medicine | 3 days | save | | | | |
| What's BEST for children with non-cystic fibrosis bronchiectasis? | Lancet Respiratory Medicine | 3 days | save | | | | |
| Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial | Lancet Respiratory Medicine | 3 days | save | | | | |
| When is the right time to discuss ECMO? | Lancet Respiratory Medicine | 7 days | save | | | | |
| Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study | Lancet Respiratory Medicine | 7 days | save | | | | |
| Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial | Lancet Respiratory Medicine | 7 days | save | | | | |
| Pulmonary hypertension associated with idiopathic interstitial pneumonia: is effective pharmacotherapy an impossible dream? | Lancet Respiratory Medicine | 7 days | save | | | | |
| Prospects and challenges of a new live tuberculosis vaccine | Lancet Respiratory Medicine | 7 days | save | | | | |
| Insights and challenges in tuberculosis vaccine development | Lancet Respiratory Medicine | 7 days | save | | | | |
| Raising new questions on best care for bronchiectasis | Lancet Respiratory Medicine | 10 days | save | | | | |
| Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis | Lancet Respiratory Medicine | 10 days | save | | | | |
| The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis | Lancet Respiratory Medicine | 10 days | save | | | | |
| Treatment duration of checkpoint inhibitors for NSCLC | Lancet Respiratory Medicine | 12 days | save | | | | |
| Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial | Lancet Respiratory Medicine | 13 days | save | | | | |
| A new frontier in ARDS trials: phenotyping before randomisation | Lancet Respiratory Medicine | 13 days | save | | | | |
| Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study | Lancet Respiratory Medicine | 33 days | save | | | | |
| Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations | Lancet Respiratory Medicine | 33 days | save | | | | |
| Biomarkers and early treatment of idiopathic pulmonary fibrosis | Lancet Respiratory Medicine | 33 days | save | | | | |
| Germline variants invited to lung cancer screening | Lancet Respiratory Medicine | 33 days | save | | | | |
| Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians | Lancet Respiratory Medicine | 34 days | save | | | | |
| Correction to Lancet Respir Med 2019; 7: 402–16 | Lancet Respiratory Medicine | 35 days | save | | | | |
| Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis | Lancet Respiratory Medicine | 41 days | save | | | | |
| The global burden of sleep apnoea | Lancet Respiratory Medicine | 41 days | save | | | | |
| Blood eosinophils as a continuous variable in the treatment of COPD: impact on the guidelines | Lancet Respiratory Medicine | 46 days | save | | | | |
| Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial | Lancet Respiratory Medicine | 46 days | save | | | | |
| Fetal tissue research: focus on the science and not the politics | Lancet Respiratory Medicine | 56 days | save | | | | |
| Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study | Lancet Respiratory Medicine | 59 days | save | | | | |
| Live attenuated influenza vaccines for African children | Lancet Respiratory Medicine | 59 days | save | | | | |
| Scientists call for US EPA to reconvene expert panel on particulate matter pollution | Lancet Respiratory Medicine | 60 days | save | | | | |
| Clean air in the ‘big smoke’ | Lancet Respiratory Medicine | 62 days | save | | | | |
| Managing tuberculosis in the Baltic states | Lancet Respiratory Medicine | 63 days | save | | | | |
| Promoting clean air: combating fake news and denial | Lancet Respiratory Medicine | 63 days | save | | | | |
| Ethnicity and spirometric indices: hostage to tunnel vision? | Lancet Respiratory Medicine | 66 days | save | | | | |
| How sustainable are new treatment strategies for NSCLC? | Lancet Respiratory Medicine | 66 days | save | | | | |
| Post-traumatic stress in the intensive care unit | Lancet Respiratory Medicine | 67 days | save | | | | |
| Efforts to tackle air pollution should focus on accountability | Lancet Respiratory Medicine | 68 days | save | | | | |
| Effects of saline or albumin fluid bolus in resuscitation: evidence from re-analysis of the FEAST trial | Lancet Respiratory Medicine | 70 days | save | | | | |
| Adverse effects of bolus fluid resuscitation—short-term benefit but long-term harm | Lancet Respiratory Medicine | 70 days | save | | | | |
| Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia | Lancet Respiratory Medicine | 73 days | save | | | | |
| Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial | Lancet Respiratory Medicine | 74 days | save | | | | |
| Finding the missing millions affected by tuberculosis is one thing; treating them is another | Lancet Respiratory Medicine | 74 days | save | | | | |
| Cardiopulmonary haemodynamics in portopulmonary hypertension | Lancet Respiratory Medicine | 74 days | save | | | | |
| Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial | Lancet Respiratory Medicine | 74 days | save | | | | |
| Inhaled hypertonic saline for 3–6-year-olds with cystic fibrosis | Lancet Respiratory Medicine | 74 days | save | | | | |
| Managing asthma in pregnancy: effects on future child health | Lancet Respiratory Medicine | 74 days | save | | | | |
| Tuberculosis: a much-needed focus on transmission | Lancet Respiratory Medicine | 83 days | save | | | | |
| Machine learning molecular classification in IPF: UIP or not UIP, that is the question | Lancet Respiratory Medicine | 90 days | save | | | | |
| Aligning use of intensive care with patient values in the USA: past, present, and future | Lancet Respiratory Medicine | 91 days | save | | | | |
| Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study | Lancet Respiratory Medicine | 91 days | save | | | | |
| | 
report | next » |
| |
